论文部分内容阅读
目的:观察吉西他滨(Gem)、奥沙利铂(L-OHP)、地塞米松(DXM)组成的GLD联合化疗方案治疗21例复发或难治性非霍奇金淋巴瘤患者的近期疗效和毒副反应。方法:21例经正规治疗后复发或难治的非霍奇金淋巴瘤患者,采用GLD方案化疗:吉西他滨(Gem)1 000 mg/m~2,静脉滴注,第1、8天;奥沙利铂(L-OHP)85 mg/m~2,静脉滴注,第1、8天;地塞米松(DXM)40 mg/d,静脉滴注,第1～4天。以3～4周为1周期,每例患者至少连用2个周期。结果:21例患者中,15例获得缓解,占71.43%。其中完全缓解(CR)5例(23.81%),部分缓解(PR)10例(47.62%)。化疗毒副作用主要为骨髓抑制。其他有轻至中度的消化系统反应等。结论:吉西他滨联合奥沙利铂、地塞米松组成的GLD联合化疗方案对治疗复发性非霍奇金淋巴瘤患者有较好的近期疗效,毒副反应轻,能明显改善患者的症状,是一个值得进一步验证的补救性化疗方案。
Objective: To observe the short-term curative effect and toxicity of GLD combined with chemotherapy consisting of gemcitabine, L-OHP and DXM in 21 patients with recurrent or refractory non-Hodgkin’s lymphoma side effects. METHODS: Twenty-one patients with non-Hodgkin’s lymphoma who were relapsed or refractory to formal treatment were treated with GLD chemotherapy: gemcitabine (Gem) 1 000 mg / m 2, iv, (L-OHP) 85 mg / m ~ 2, intravenous drip, on the first and eighth days; dexamethasone (DXM) 40 mg / d, intravenous drip, the first to 4 days. To 3 to 4 weeks for a cycle, each patient at least two cycles. Results: Of the 21 patients, 15 were relieved, accounting for 71.43%. There were 5 cases (23.81%) of complete remission (CR) and 10 cases (47.62%) of partial remission (PR). The main side effects of chemotherapy for bone marrow suppression. Other mild to moderate digestive reactions. Conclusion: The combination therapy of gemcitabine plus oxaliplatin and dexamethasone has a good short-term curative effect in the treatment of patients with recurrent non-Hodgkin’s lymphoma. It has the advantages of mild side effects and significant improvement in patients’ symptoms. Remedial chemotherapy regimen worth further validation.